Abstract: Complex regional pain syndrome (CRPS) is an illdefined, poorly understood disorder that causes significant morbidity in those who suffer from it. It is estimated that up to 20% to 35% of patients will remain incapacitated indefinitely and that only 20% to 30% of patients will be able to return to their previous full-time employment. A number of treatments, interventional and noninterventional, have been posited as possible therapies for CRPS. We discuss and review here the evidence-based rationale for pharmacologic therapy for CRPS.
T he disorder now known as complex regional pain syndrome (CRPS) has undergone a complex evolution.
1,2 CRPS was first recognized in 1864 when Silas Weir Mitchell observed that soldiers sometimes suffered from severe, long lasting, burning pain after nerve injuries. He referred to this phenomenon as ''causalgia. '' 3 Rene´Leriche is credited with the first therapy for this condition, describing pain relief after stripping of a periarterial nerve plexus in a patient with causalgia of an ischemic limb. 4 In 1953, Bonica coined the term reflex sympathetic dystrophy (RSD), recognizing for the first time that RSD is a condition separate from causalgia. Today, the accepted terms for this spectrum of disease are CRPS I, the equivalent of RSD, and CRPS II, which has also been called causalgia. As will be discussed, the classification of this spectrum of disorders continues to develop.
CRPS I
The incidence of CRPS I varies widely, from 0.05% to 35%, based upon the population being studied. [5] [6] [7] [8] It represents about 90% of cases of CRPS. 8 CRPS I is defined as a syndrome that develops after an initiating noxious event, is not limited to the distribution of a single peripheral nerve, and is disproportionate to the inciting event. 9 It is frequently associated with other signs and symptoms such as edema, variegated skin color, variable skin blood flow, abnormal sudomotor activity in the region of the pain, allodynia, or hyperalgesia. There are 4 diagnostic criteria for CRPS I, 2 of which must be satisfied to make the diagnosis. 10 They are (1) the presence of an inciting noxious event or a cause of immobilization; (2) continuing pain, allodynia, or hyperalgesia with which the pain is disproportionate to the inciting event; (3) evidence of edema, variegated skin color, variable skin blood flow, abnormal sudomotor activity in the region of the pain; and (4) absence of conditions that would otherwise account for the pain.
CRPS II
CRPS II is considered more rare than CRPS I and is defined as burning pain, allodynia, and hyperpathia usually in the hand or foot after partial injury of a nerve or one of its major branches. 9 There are 3 diagnostic criteria for CRPS II, all of which must be met to make the diagnosis. 10 They are (1) the presence of continuing pain, allodynia, or hyperalgesia after a nerve injury, not necessarily limited to the distribution of the injured nerve; (2) evidence of edema, variegated skin color, variable skin blood flow, abnormal sudomotor activity in the region of the pain; and (3) absence of conditions that would otherwise account for the pain. A demonstrable nerve lesion must also be present to make the diagnosis.
proposed are the following: (1) continuing pain disproportionate to any inciting event; (2) at least 1 symptom in each of the 4 categories; and (3) at least 1 sign in 2 of the 4 categories. It seems that in light of the controversy regarding diagnostic criteria so soon after describing CRPS, it is likely that yet another term to describe this condition may emerge. 12 
PATHOPHYSIOLOGY
The etiology and pathogenesis of CRPS are poorly understood, but it may involve formation of a reflex arc after an inciting event. 13 A study examining inciting events in patients with CRPS revealed that soft tissue injury was the inciting event in 40% of the cases, fractures in 25%, myocardial infarction in 12%, and cerebrovascular accidents in 3%. 13 There are a plethora of other reported etiologies, including surgery, particularly arthroscopy, 14 myocardial ischemia or stroke/hemiplegia, 15 arteriovenous graft placement for hemodialysis, 16 and even administration of cyclosporine. 17 Interestingly, 1 report showed no inciting event in 35% of the CRPS patients. 10 Among the more popular theories regarding the mechanism of persistent pain and allodynia in CRPS is overproduction of inflammatory mediators and algesic neuropeptides by peripheral nerves. This hypothesis is supported by evidence of increased circulating levels of substance P in those with CRPS I when compared with those without. 18 Additionally, high concentrations of proinflammatory cytokines [tumor necrosis factor-a (TNF-a), interleukin-6] have been found in blisters overlying CRPS-affected skin. 19 The role of the central nervous system, particularly in those patients who exhibit signs and symptoms of CRPS without an inciting event, has been explored, and a significant CNS involvement in the pathogenesis of CRPS has been postulated. For example, lowering core body temperature and thereby increasing hypothalamic autonomic output has been shown to increase the area of hyperalgesia in CRPS patients, which perhaps supports a centrally mediated mechanism. 20 Additionally, unilateral sympathetic nerve block has been shown to produce bilateral symptomatic improvement (on the untreated side). 21 Finally, genetic predisposition has been explored as a possible contributing factor to the development of CRPS. In 1 study, female patients with CRPS were twice as likely to test positive for HLA-A3, B7, and DR2 (15) major histocompatibility complex antigens, suggesting a possible genetic factor in the development of CRPS. 22 
PHARMACOLOGIC THERAPY FOR CRPS
There is a relative paucity of randomized controlled trials investigating the efficacy of various pharmacologic therapies for CRPS. Given the similarities between neuropathic pain and CRPS, many of the drugs that have been show to be effective in the treatment of neuropathic pain are used to treat CRPS on a trialand-error basis. To date, 4 pharmacologic treatment modalities have been studied as therapies for CRPS and found to significantly improve symptoms. They are anticonvulsants, bisphosphonates, oral glucocorticoids, and calcitonin. Other treatments, such as tricyclic antidepressants (TCAs), nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids are typically considered first-line therapies for CRPS, though they have not been formally studied. Finally, other therapies are under investigation, including topical capsaicin and lidocaine, sympathetic blockers such as clonidine, phentolamine, and ketansarin, intravenous (IV) lidocaine and bretylium, and topical free radical scavengers such as dimethyl sulfoxide (DMSO).
ANTICONVULSANTS
Anticonvulsants have been shown to be particularly effective in treatment of chronic pain, especially pain that is burning or sharp in quality. The best studied of the anticonvulsants is gabapentin. Gabapentin has been widely studied in the treatment of neuropathic pain, including diabetic neuropathy and postherpetic neuralgia, and based on these studies it is generally accepted that patients being treated with gabapentin can expect a mean reduction in pain score of 2.05 points on an 11-point numerical rating scale compared with a reduction of 0.94 points if they had taken placebo. 23 Though large randomized controlled trials have yet to be carried out, successful use of gabapentin in treatment of CRPS has been reported. 24, 25 In 1 randomized controlled trial, gabapentin was found to result in mild pain relief versus placebo in a series of 58 patients. 26 Lamotrigine, carbamazepine, phenytoin, and pregabalin seem to have some efficacy in treatment of CRPS, but have yet to be formally studied. Pregabalin in particular has become more popular among experienced clinicians. Though the exact mechanism of action of pregabalin remains unclear, it occupies the same binding site on the presynaptic calcium channel. It is 6 times more potent at the calcium channel than gabapentin. 25 The result of this binding is a decrease in release of a number of neurotransmitters and an overall inhibition of neuronal excitability.
BISPHOSHONATES
Bisphosphonates, which were initially used to prevent bone loss in CRPS patients, 27 also seem to be useful in pain relief. Numerous randomized controlled studies have been pursued to evaluate the efficacy of bisphosphonates in treatment of CRPS. In 1 series, 32 patients were randomized to either IV clodronate or placebo for a 10-day course. After 40 days, those who received clodronate experienced a statistically significant improvement in pain. 28 Another series of 29 patients receiving IV pamidronate revealed the drug to be an effective treatment in refractory CRPS, 29 and in yet another series of 23 patients with severe, recalcitrant CRPS, pamidronate showed a significant decrease in symptoms at 30 days. 30 Interestingly, both parenteral and enteral alendronate are associated with improved symptoms. 31, 32 The mechanism of action of bisphosphonates in relieving pain associated with CRPS is not known.
ORAL GLUCOCORTICOIDS
There is some evidence that oral glucocorticoids, such as prednisone, may be effective in treating CRPS. 33 Two small randomized controlled trials have examined the effect of glucocorticoids. One trial included 36 patients suffering from CRPS as a result of cerebrovascular accident. At 10 days, 31 of 36 patients treated with low-dose oral prednisone were nearly symptom free. 34 Another included 23 patients who were randomly assigned to prednisone 10 mg 3 times a day or placebo. At 12 weeks, more than 75% of prednisone-treated patients showed clinical improvement. 35 Compared with NSAIDs, glucocorticoids seem to be significantly superior in treating CRPS. In 1 study, a greater proportion of patients receiving steroids met criteria for improvement than did those receiving NSAIDs. 34 There have been additional reports of successful use of oral glucocorticoids, particularly for the treatment of lower extremity CRPS. [36] [37] [38] Early use of corticosteroids seems to be beneficial based on studies that have been performed. Short-term use of steroids seems safe and effective, though long-term use is generally discouraged.
CALCITONIN
There have been 5 clinical trials investigating the use of calcitonin for treatment of CRPS, which reveal conflicting data. Generally, those patients receiving calcitonin tend to experience relief in 4 to 5 days, with a treatment course of 2 to 3 weeks. The putative benefit is thought to arise from the hormone's ability to retard bone resorption and have a mitigating effect on inflammation of the vasculature in the inflammatory state, though the exact mechanism of action remains unclear. Two of these trials were randomized, placebo controlled trials in which calcitonin was administered either via nasal spray or injection. The patients in this trial experienced a significant improvement in symptoms over placebo. 39, 40 Another trial examined 35 patients who were randomized to either calcitonin or paracetamol. This trial found that although both groups recovered, there was no significant difference between the control and calcitonin group in terms of symptom improvement. 41 Despite these findings, the optimum dose of calcitonin remains unclear, and cost of long-term calcitonin remains prohibitive at this time.
OTHER THERAPIES
Though anticonvulsants, bisphosphonates, glucocorticoids, and calcitonin are the only therapies that have been adequately studied for CRPS, other treatments have been reported to be beneficial in the treatment of CRPS. These therapies are considered mainstays of CRPS treatment based on their documented efficacy in treating neuropathic pain and their anecdotal efficacy in treating CRPS. TCAs have long been a mainstay of treatment for chronic pain (particularly neuropathic pain) syndromes, and they are routinely prescribed for patients with CRPS. NSAIDs, and in severe cases, opioids such as methadone have been used to treat symptoms of CRPS.
TCAs have been well studied and have been shown to be effective for neuropathic pain, particularly pain associated with diabetic neuropathy. [42] [43] [44] It stands to reason, then, that TCAs may have some efficacy in treating CRPS. Indeed, TCAs are traditionally used to treat CRPS as part of a multimodal therapy approach. To date, there have been no randomized controlled trials performed to evaluate the efficacy of TCAs in specifically reducing CRPS symptomatology. 45 Nonetheless, they remain a commonly prescribed medication for CRPS due to their perceived benefit. For patients who are concomitantly depressed, TCAs may represent a reasonable choice. Other antidepressants, such as selective serotonin reuptake inhibitors, have shown similar promise in treating neuropathic pain, though they have been even less rigorously studied. 46, 47 Patients with CRPS typically are prescribed maintenance medications they take on a daily basis (TCAs, anticonvulsants), but they frequently require ''rescue'' agents to manage symptoms that arise despite maintenance therapy. The most commonly prescribed are NSAIDs and opioids. NSAIDs show particular benefit in cases where there is a large degree of inflammation in the affected limb, though most available literature is in patients with peripheral neuropathy. 45, 48 NSAIDs even seem to slow the progression of diabetic neuropathy. 48 COX-2 inhibitors are frequently prescribed, but have not been tested in treatment of CRPS. The use of opioids in CRPS patients is controversial. 49 Clearly, there is concern regarding tolerance and dependence when opioids are available to those with any chronic pain disorder. Thus, they are frequently used for rescue when patients are having a pain crisis. Opioids have not been studied specifically for CRPS, but intermediate-term studies have been done evaluating the efficacy of opioids in treating neuropathic pain. On the basis of these studies, there is clearly a benefit of opioids over placebo. 50 Adverse events are frequent, however, and safety remains to be formally studied.
FUTURE DIRECTIONS
A number of additional putative therapies for CRPS have emerged that warrant discussion. Among them are systemic lidocaine, topical lidocaine, a-adrenergic antagonists, calcium channel antagonists, N-methyl D-aspartate (NMDA) antagonists such as memantine and ketamine, thalidomide, and free radical scavengers such as DMSO.
Lidocaine, both topical and systemic, has shown some promise as a possible therapy for CRPS. Lidocaine patches are used frequently as adjuvant therapy in many neuropathic pain states. The putative mechanism is related to known overexpression of sodium channels and augmentation of their activity in neuropathic pain affected tissue. 51 Devers and Galer 52 assessed 16 patients who used 5% lidocaine patches, and 81% experienced moderate pain relief. The safety of such patches has been examined. In patients wearing 5% lidocaine patches for 72 hours, plasma lidocaine levels remained significantly below the toxic threshold. 53 Systemic lidocaine, administered as IV infusion, is particularly interesting because it seems to provide lasting pain relief. A preliminary study in which patients were given 5 mg/kg lidocaine over 1 hour resulted in patients experiencing immediate pain relief that lasted for 14 days. 54 Patients with CRPS have disproportionately higher levels of circulating catecholamines. 55 It has been theorized that pain associated with CRPS can be attributed in part to ''catecholamine oversensitization,'' which in turn triggers nociceptive firing. Thus, a-adrenergic antagonists have been investigated as a possible therapy for CRPS as a method to decrease peripheral nerve sensitivity to these stimuli. Phentolamine has been shown to have some efficacy in reducing CRPS symptoms in the lower extremity. Its half-life is 15 minutes, preventing its routine use, though those patients in whom it is effective are more likely to respond to sympathetic block. There have been case reports of success with phenoxybenzamine (oral and IV) and terazosin (oral). 56, 57 Oral and IV clonidine have been used on a theoretical basis with some success despite the lack of evidence supporting it. There has also been some clinical benefits shown in the use of topical clonidine. 58 Patients with CRPS frequently have associated vasospasm in the affected body areas, contributing to pain. Calcium channel antagonists have been proposed as an adjunct to conventional CRPS therapy for that reason. Treatment with nifedipine resulted in significant symptom relief in 1 series. 57 Oral nifedipine resulted in significant improvement in another series of 3 patients, though maintenance doses were required for sustained relief. 59 Animal models in peripheral nerve injury show an up-regulation of NMDA receptors, and similar animal models show decreased pain behaviors after administration of IV ketamine. On the basis of these findings, NMDA receptor antagonists have been postulated to have a role in treatment of CRPS. In 1 series of 6 patients, memantine produced a significant pain reduction even at 6 months of follow-up. Ketamine has been showed to be superior to morphine and placebo in treatment of postherpetic pain, 60 and there have been 2 reports of epidural ketamine being effective in treatment of CRPS. 61, 62 There has been a preliminary report of a patient with severe CRPS who was treated effectively with oral thalidomide. This patient experienced lasting pain relief of low-dose maintenance thalidomide. 63 One must use caution in considering this drug due to its significant teratogenicity. Little is known about the mechanism of action of thalidomide in CRPS, indeed, little is known about the mechanism of its benefit to those diagnosed with myeloma. Thalidomide inhibits production of TNF-a and other cytokines. As previously stated, TNF-a and interleukin-6 were detected at significantly higher levels in suction blister fluid collected from the involved extremity of patients with CRPS compared with the noninvolved extremity. Although the role of these cytokines in CRPS requires further study, it seems that they decrease the threshold for firing of pain fibers. Putatively, in this manner thalidomide could result in improvement of symptoms.
Again relying on the theory that CRPS is an exaggerated tissue response to nerve injury, several animal studies have found that there is likely a significant role of free radical oxygen species in the pathogenesis of CRPS. [64] [65] [66] [67] The applicability of free radical scavengers in treating human pain states such as CRPS is currently undergoing investigation. In 1 randomized controlled study, patients were treated with either topical DMSO 50% or N-acetylcysteine 600 mg orally 3 times daily, each for 17 weeks. Both treatments resulted in improvement of symptoms. There was no significant difference in improvement between the 2 treatments. 68 
CONCLUSIONS
Although knowledge regarding CRPS has burgeoned over the past several years, it is still relatively poorly understood. Many therapeutic approaches have been reported, and evidence suggests that some pharmacologic interventions are more effective than others. On the basis of an expanding body of evidence, a multifaceted treatment approach is most likely to result in improvement of CRPS symptoms, with most clinicians recommending a combination of psychologic, pharmacologic, and interventional approaches. Psychologic and interventional treatments are outside the scope of this review, though both can lead to a significant improvement in symptoms.
Typically, pharmacologic agents known to be effective for neuropathic pain are used on a trial-anderror basis. Gabapentin and pregabalin are considered first-line agents. It has been well demonstrated that these medications reduce the painful symptoms of CRPS. Though the body of evidence supporting use of TCAs is considerably larger, they are associated with more side effects that may be undesirable or dangerous. Nevertheless, they are considered to be good adjunct drugs when membrane stabilizers alone are not sufficiently effective. TCAs can be added if membrane stabilizers are ineffective. Calcitonin may be useful based on available evidence, but the route of administration and cost may prove prohibitive for use in routine cases. Corticosteroids can be added, but there is limited evidence for their efficacy and they have significant side effects. Other therapies, such as opiates, NMDA antagonists, and calcium channel blockers have been reported to improve symptoms but there is no evidence to support their use. These therapies, though promising, require further investigation.
